Refametinib
- Generic Name
- Refametinib
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20F3IN2O5S
- CAS Number
- 923032-37-5
- Unique Ingredient Identifier
- JPX07AFM0N
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT02346032
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT02168777
Effect of Ketoconazole on the Pharmacokinetics of Refametinib
- First Posted Date
- 2013-08-20
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT01925638
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT01915602
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT01915589
BAY86-9766 Plus Gemcitabine Phase I Study in Asian
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 23
- Registration Number
- NCT01764828
Japanese BAY86-9766 Monotherapy Phase I Study
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT01179295
RDEA119 and Sorafenib Combination Dose Escalation Study
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT00785226
- Locations
- 🇺🇸
UPenn, Philadelphia, Pennsylvania, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center, Los Angeles, California, United States
Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 69
- Registration Number
- NCT00610194
- Locations
- 🇺🇸
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸Roswell Park Cancer, Buffalo, New York, United States
🇺🇸UCHSC, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath